By Fineline Cube Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study of tilrekimig (PF-07275315), an investigational trispecific antibody targeting IL-4, IL-13, and TSLP, in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, with tilrekimig demonstrating statistically significant EASI-75 responses versus placebo, including 51.9% placebo-adjusted response at the middle dose with monthly dosing. The favorable efficacy and safety profile supports acceleration to Phase 3, with a pivotal AD study planned for 2026 initiation.
Clinical Trial Results
| Endpoint | Tilrekimig (Low/Mid/High Dose) | Placebo | Outcome |
|---|---|---|---|
| Primary: EASI-75 at Week 16 | 38.7% / 51.9% / 49.4% (placebo-adjusted) | Reference | Statistically significant; dose-responsive efficacy |
| Dosing Regimen | Monthly (Stage 2 evaluation) | — | Competitive with Q2W/Q4W standard biologics |
| Safety | Well-tolerated; favorable profile | — | No unexpected safety signals |
| Study Design | Stage 1: dose-ranging; Stage 2: monthly dosing confirmation | — | Robust Phase 2b design |
EASI-75 Context:
- Eczema Area and Severity Index 75% improvement – standard AD efficacy endpoint
- 51.9% mid-dose response competitive with dupilumab (~50-60%) and lebrikizumab (~50%) in similar populations
Drug Profile & Mechanism
| Attribute | Tilrekimib (PF-07275315) Specification |
|---|---|
| Drug Class | Trispecific antibody (first-in-class mechanism) |
| Targets | IL-4 + IL-13 + TSLP (three key Th2 cytokines) |
| Mechanism | Simultaneous blockade of: • IL-4/IL-13 (Th2 inflammation, barrier dysfunction) • TSLP (upstream master switch for Type 2 immunity) |
| Synergy | Comprehensive Th2 pathway shutdown vs. single or dual targeting |
| Dosing Potential | Once-monthly (supported by Stage 2 data) |
| Indications in Development | Atopic dermatitis (lead); asthma; chronic obstructive pulmonary disease (COPD) |
Scientific Rationale:
- IL-4/IL-13: Established AD drivers (dupilumab target); barrier repair and pruritus control
- TSLP: Upstream amplifier; tezepelumab validated target for severe, refractory disease
- Trispecific Advantage: Single molecule achieves triple blockade; potential for superior efficacy in heterogeneous AD populations
Strategic Context & Development Outlook
| Factor | Implication |
|---|---|
| Phase 3 Acceleration | Pivotal AD study on track for 2026 start; rapid progression given competitive urgency |
| Competitive Positioning | Challenges dupilumab (IL-4Rα) and lebrikizumab (IL-13) with triple mechanism; monthly dosing convenience advantage |
| Respiratory Expansion | Asthma and COPD indications leverage same Th2 biology; platform potential across inflammatory franchise |
| Pfizer Immunology | Complements abrocitinib (JAK1, oral) with biologic option; addresses unmet need in moderate-severe AD |
| Revenue Potential | AD market alone $15+ billion globally; tilrekimig could capture 10-15% share if approved |
Competitive Landscape
| Competitor | Product | Mechanism | Dosing | Tilrekimig Differentiation |
|---|---|---|---|---|
| Sanofi/Regeneron | Dupixent (dupilumab) | IL-4Rα blockade (IL-4 + IL-13) | Q2W | Adds TSLP targeting; monthly convenience |
| Eli Lilly | Ebglyss (lebrikizumab) | IL-13 mAb | Q2W/Q4W | Triple vs. single cytokine blockade |
| Amgen/AZ | Tezspire (tezepelumab) | TSLP mAb | Q4W | Adds IL-4/IL-13 for comprehensive Th2 suppression |
| Pfizer | Tilrekimig | IL-4 + IL-13 + TSLP trispecific | Monthly | First trispecific; potential best-in-class efficacy |
Development Timeline
| Phase | Timeline | Objectives |
|---|---|---|
| Phase 2 | Complete | Efficacy, dose-ranging, monthly dosing confirmation |
| Phase 3 (AD) | 2026 initiation | Pivotal efficacy vs. placebo and/or active comparator; safety database expansion |
| Phase 2/3 (Asthma) | 2026-2027 | Proof-of-concept in Th2-high asthma; exacerbation reduction |
| Phase 2 (COPD) | 2027+ | Th2-endotype COPD evaluation |
| NDA Filing | 2028-2029 | U.S., EU, Japan simultaneous submissions anticipated |
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Phase 3 initiation timelines, competitive positioning, and market potential for tilrekimig. Actual results may differ due to trial execution risks, competitive dynamics with established biologics, and manufacturing scale-up for trispecific antibody production.-Fineline Info & Tech